Characterization of CD24 expression in intraductal papillary mucinous neoplasms and ductal carcinoma of the pancreas-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Characterization of CD24 expression in intraductal papillary mucinous neoplasms and ductal carcinoma of the pancreas

Published:2010-10 Issue:10 Volume:41 Page:1466-1474
ISSN:0046-8177
Container-title:Human Pathology
language:en
Short-container-title:Human Pathology

Author:

Ikenaga Naoki,Ohuchida Kenoki,Mizumoto Kazuhiro,Yu Jun,Kayashima Tadashi,Hayashi Akifumi,Nakata Kohei,Tanaka Masao

Funder

Takeda Science Foundation

Heiwa Nakajima Foundation

Pancreas Research Foundation of Japan

Ministry of Education, Culture, Sports, Science and Technology

Publisher

Elsevier BV

Subject

Pathology and Forensic Medicine

Reference36 articles.

1. Prognosis of human pancreatic adenocarcinoma: review of clinical and histopathological variables and possible uses of new molecular methods;Eskelinen;Eur J Surg,1999

2. Pancreatic cancer;Yeo;Curr Probl Cancer,2002

3. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database;Sener;J Am Coll Surg,1999

4. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma;Wagner;Br J Surg,2004

5. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry;Carpelan-Holmstrom;Gut,2005

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unravelling CD24‐Siglec‐10 pathway: Cancer immunotherapy from basic science to clinical studies;Immunology;2024-08-11

2. Cell of Origin of Pancreatic cancer;Pancreas;2024-01-29

3. Pancreatic cancer stem cells and inflammation: milestones achieved and challenges ahead;Cancer Stem Cells and Signaling Pathways;2024

4. Emerging Immune Checkpoint Molecules on Cancer Cells: CD24 and CD200;International Journal of Molecular Sciences;2023-10-11

5. CD24 blockade as a novel strategy for cancer treatment;International Immunopharmacology;2023-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3